Radboud university medical center and UMC Utrecht are working on a joint research project to discover whether the tuberculosis (BCG) vaccine reduces the risk of infection with the coronavirus in people aged 60 or older, or the severity of the symptoms in the event of infection. A total of 1,600 people may take part in the study, which starts today. Half of the study participants will be given the vaccine, the other half will not.
The elderly have a higher chance of becoming seriously ill as a result of the coronavirus. Also, if infected, they are more at risk of dying from the infection. There is currently no vaccine against the coronavirus, and no other way of protecting the elderly from infection. However, previous research shows that the BCG vaccine protects not just against tuberculosis, but that it can also increase people’s immunity to other viruses.
It is unclear whether the BCG vaccine can also provide some level of protection from the coronavirus. The aim of this study is therefore to find out whether it does. The study should answer the question whether the BCG vaccine provides protection from the coronavirus and/or whether it reduces the severity of the symptoms in the elderly. This is the second study carried out by the Radboud university medical center and UMC Utrecht into the effect of the BCG vaccine on the coronavirus. The first study focused specifically on healthcare workers, whereas this study focuses exclusively on the elderly.
BCG is the most widely administered vaccine in the world and is used in many countries to prevent tuberculosis. For this study, the hospitals will obtain the BCG vaccine directly from the Dutch National Institute for Public Health and the Environment (RIVM). The study will therefore not affect the availability of the vaccine for regular use by the municipal public health service (GGD) in the Netherlands. Participants in the study must be aged 60 or older.
Related news items
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more
Retirement of RIMLS Laboratory Assistant Nelly Mulders-Langen19 May 2020
After more than 45 years, Nelly said goodbye to "her" Radboudumc. We are going to miss her dedication and collegiality, but we wish her al the best for the future in good health.read more